BCG vaccine - Serum Institute of India/Vakzine Projekt Management
Alternative Names: BCG VPM 1002; BCG-vaccine-Vakzine-Projekt-Management; rBCG-delta-ureC-Hly; rBCGdeltaUreCHly; VPM-1002; VPM-1002BCLatest Information Update: 23 Jul 2026
At a glance
- Originator Max Planck Institute for Infection Biology
- Developer Max Planck Institute for Infection Biology; Serum Institute of India; Swiss Group for Clinical Cancer Research; Vakzine Projekt Management
- Class COVID-19 vaccines; Tuberculosis vaccines; Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections; Respiratory tract infections; Tuberculosis
- Phase II Bladder cancer
Most Recent Events
- 29 May 2026 Efficacy and safety data from a phase II trial in Bladder cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 30 Oct 2024 Serum Institute of India and Vakzine Projekt Management completes a phase-III clinical trials in Tuberculosis (In neonates, Prevention) in Kenya, South Africa, Gabon, Tanzania and Uganda (NCT04351685)
- 24 Jun 2022 Phase-II clinical trials in Bladder cancer in Switzerland (Intravesicular) (NCT04630730)